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1. Introduction 
Posttrasplant lymphoproliferative disorders (PTLD) represent a wide spectrum of 
pathologic and clinical manifestations that occur in the setting of depressed T-cell function 
and altered immune surveillance, such as is observed in the setting of solid organ 
transplantation (SOT).  PTLD is a major contributor to long-term morbidity and mortality in 
this population and is the most common cancer observed in children following SOT. 
(Webber et al., 2006) Many cases are associated with Epstein-Barr virus (EBV) infection and 
most, but not all, are of host origin. (Petit et al., 2002, Taylor et al., 2005)  This article reviews 
the pathology, epidemiology, risk factors, and clinical aspects of PTLD, and identifies the 
need for ongoing systematic study of complex biologic and therapeutic questions. 
2. Pathology 
PTLD encompasses a remarkable diversity of pathologic conditions. The most commonly 
used pathologic classification scheme is the World Health Organization (WHO) 
categorization, outlined in Table 1. (Swerdlow et al., 2008) Pathologic evaluation requires 
assessment of tissue architecture and cytologic features including immunophenotype; 
excisional biopsies are preferred and tissue samples should be submitted fresh rather than in 
formalin. It must be established if the PTLD is EBV-associated disease, for example by EBV-
encoded RNA in situ hybridization (ISH) testing of diagnostic tissues. Cytogenetic studies 
assist with determination of clonality (immunoglobulin heavy [IgH] gene rearrangement; T-
cell receptor gene rearrangement) and identify disease-associated chromosomal 
abnormalities. It is important to exclude other diagnoses including infection, inflammatory 
processes or rejection. Characteristics that suggest but are not pathognomonic of PTLD 
include enlarged nodules, mass lesions, lymphoid atypia, a very B cell rich infiltrate, 
extensive necrosis in the infiltrate and numerous EBV+ cells. (Dharnidharka, 2010)   PTLD 
may be observed simultaneously at different sites in a patient, and a patient may have two 
different types of PTLD simultaneously or subsequently. (Blaes & Morrison, 2010) 
3. Epidemiology and risk factors 
The overall incidence of lymphoproliferative disease varies from 1 to 20% depending on the 
type of transplant and other risk factors. (Vegso et al., 2010) The frequency of PTLD is higher 
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in childhood; regardless of the transplanted organ the incidence is 2 to 3-fold compared to 
adults. The principal risk factors in the development of PTLD are the degree of 
immunosuppression and the EBV serostatus of the recipient. (Dharnidharka et al., 2001; 
McDonald et al., 2008; Opelz & Dohler, 2004) Similarly, younger age at transplant is a strong 
risk factor for PTLD, but likely reflects the proportion of recipients who are EBV-
seronegative. Other risks described include past history of malignancy, the degree of HLA-
compatibility and the occurrence and severity of acute rejection, the type of the transplanted 
organ, and the immunosuppressive drugs used. (Bakker et al., 2005b; Taylor et al., 2005; 
Tsao & Hsi, 2007)   
3.1 Pathogenic mechanism of EBV 
EBV is a polyclonal stimulator of B-cell proliferation. More than 90% of the world’s 
population is infected with EBV and infected individuals remain lifelong carriers of the 
virus. (Rickinson & Kieff, 1996) The life cycle of EBV is outlined in Fig. 1. Primary infection 
occurs through the oropharynx, where the virus infects resting B cells. The expression of 
viral proteins induces polyclonal proliferation of infected B-cells and some of these 
differentiate into memory cells which carry the virus in a latent form. (Thorley-Lawson, 2001) 
Among immunocompetent hosts, control of virus spread and of unrestrained infected B-cell 
proliferation is maintained by the development of a specific immune response. 
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Fig. 1. EBV Life Cycle. (Courtesy of Dr. Thomas G. Gross) 
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Pathologic Categories of PTLD 
Category Description 
Early lesions 
 Reactive Plasmatic Hyperplasia 
 
 Infectious mononucleosis-like 
 Lymphoid proliferations with preservation of normal tissue 
architecture. 
 In some cases just prominent follicular hyperplasia is seen.  
 Most of these early PTLD cases occur within a relatively short 
time after transplantation. 
 Polyclonal B cells. 
 More frequently in previously EBV-naive SOT recipients. 
 EBV often positive. 
(Swerdlow et al., 2008). 
Polymorphic 
 Morphology shows destruction of the underlying architecture 
of the tissue with perineural and blood vessel invasion. 
 Heterogeneous population with a full range of B-cell 
maturation and includes areas that seem more monomorphic, 
suggesting a continuum between polymorphic and 
monomorphic disease.  
 EBV often positive. 
 Monoclonal B cells, nonclonal T cells. 
 BCL6 somatic hypermutations may be seen. 
(Swerdlow et al., 2008). 
Monomorphic 
B-cell neoplasms 
 Diffuse large B-cell lymphoma 
 Burkitt lymphoma 
 Plasma cell myeloma 
 Plasmacytoma-like lesion 
 Other 
T-cell Neoplasms 
 Peripheral T-cell lymphoma, not 
otherwise  specified 
 Hepato-splenic  
 Other 
 Classified according to the B-cell or T/natural killer (NK)-cell 
neoplasms described in the immunocompetent host.   
 Architectural effacement usually seen. 
 EBV +/-. 
 Clonal B cells or T cells. 
 Markers of oncogenes and tumor suppressor genes (eg, C-myc, 
N-ras, and p53) may be used to facilitate diagnosis in more 
complex cases. 
 Recurrent chromosomal abnormalities have been reported in 
some series of B-cell PTLD and may portend a worse prognosis. 
(Chadburn et al., 1997; Djorkic et al., 2006; Maecker et al., 2007; 
Swerdlow et al., 2008). 
Classical Hodgkin lymphoma 
 Primarily among renal transplant recipients. 
 Should fulfill the criteria for classical Hodgkin lymphoma 
recognized in the immunocompetent host as, Reed-Sternberg-
like cells may be seen in early, polymorphic, and some 
monomorphic PTLD.  
 The expression pattern of EBV proteins (EBV-latency pattern) 
may aid in the diagnosis of cHL. 
 Architectural effacement usually seen. 
 EBV almost always positive. 
 IgH not easily demonstrated. 
(Pitman et al., 2006; Ranganathan et al., 2004; Rohr et al., 2008; 
Swerdlow et al., 2008).  
Table 1. WHO classification of PTLD. 
In a persistent infection, EBV antigen-specific T cells are maintained at a frequency of 1% to 
5% of peripheral blood T cells to immune survey and eliminate reactivating/ proliferating 
infected B cells when they express the growth program. (Steven et al., 1996) T cell–mediated 
responses to the immunogenic proteins prevent outgrowth of EBV-infected B cells. In 
contrast, when T cell–mediated responses are impaired, uncontrolled proliferation of EBV-
infected B cells will lead to the development of EBV-associated lymphoproliferative 
diseases. The disease is polyclonal in the beginning, however infected cells may then acquire 
genetic alterations that promote monoclonal lymphoma formation. The existence of EBV-
unrelated PTLD supports the theory of a pathologic interaction between genetic aberration, 
viral oncogenes, impaired immunity and chronic antigen stimulation. (Nourse et al., 2011) 
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3.2 EBV+ vs EBV- 
In children PTLD is usually induced by primary EBV infection which may occur via 
transmission from the allograft or the natural route via salivary secretion. Pediatric patients 
in particular are often EBV-seronegative, but around 90% will be positive at 6 months post-
transplant. (Newell et al., 1996) However not all EBV-seronegative SOT recipients develop 
PTLD. (Guthery et al., 2003; Tsao & Hsi, 2007) In one pediatric report of pediatric liver 
transplant  recipients, it was found that no seropositive patients developed PTLD following 
liver transplant; but 10.5% of patients who were seronegative prior to transplant developed 
PTLD. (Ho et al., 1988)  The EBV status of the donor and the recipient is a relevant factor; the 
risk of PTLD increases 10 to 50-fold when the recipient is EBV-seronegative and the donor is 
EBV-seropositive. (McDonald et al., 2008, Tsao & Hsi, 2007) Of note, EBV cannot be detected 
in 15%–40% of cases of PTLD. PTLD was historically considered an early phenomenon with 
most cases reported within the first year following transplant and attributed to the more 
intense immunosuppression used for induction therapy or exposure of the EBV-
seronegative host to the virus. (Faull et al., 2005; Webber et al., 2006).More recent data 
suggest that the median time is later, at approximately 3 years after SOT. ( Evens et al., 2010; 
Ghobrial et al., 2010; Knight et al., 2009; Maecker et al., 2007) This is partly due to an increase 
in the diagnosis of EBV-unrelated disease. Multiple reports have shown that EBV-unrelated 
PTLD occurs later after SOT, most commonly after 3 to 5 years. (Dotti et al., 2002; Mamzer-
Bruneel et al., 2000) The incidence of EBV-unrelated PTLD has been increasing and may be 
explained by changing immunosuppressive regimens, longer survival after SOT, and an 
improvement in the  diagnosis. (Nelson et al., 2000) EBV-related and EBV-unrelated PTLD 
usually have different clinical manifestations. EBV-unrelated PTLD is usually a 
monomorphic disease with late manifestation and has historically carried a poor prognosis. 
(Dotti et al., 2002; Leblond et al., 1998; Nelson et al., 2000; Taylor et al., 2005)   Recent data 
shows an improved response to treatment, which could be explained both by improvements 
in treatment strategies of the tumors and by improved supportive care. (Elstrom et al., 2006; 
Evens et al., 2010; Knight et al., 2009; Maecker et al., 2007) 
3.3 Immunosuppression 
In the absence of a reliable and reproducible method to measure intensity of 
immunosuppression, it is difficult to assess the effect of individual immunosuppressive 
agents on the risk of developing PTLD.  In addition there is often a learning curve with new 
agents, such that the incidence of PTLD may be higher when an agent is first introduced to 
clinical care. (Nourse et al., 2011; Webster et al., 2005) It does appear that increasing T cell–
specificity of immunosuppression is associated with a higher incidence of PTLD. The use of 
antibody preparations that deplete T cells has been identified as a risk factor for PTLD in 
early studies by both univariate and multivariate analyses. ( Faull et al., 2005; Kirk et al., 
2007; Opelz & Dohler, 2004; Yang et al., 2008) However, data from multiple transplant 
registries have demonstrated mixed results regarding a direct association between the use of 
Thymoglobulin and the risk of developing PTLD. (Marks et al., 2011) Quinlan et al. in a 
retrospective cohort study among 156,740 kidney transplant recipients reported that the use 
of antibody induction or antirejection therapies was not associated with PTLD risk, even 
when restricted to T-cell-based therapies, in contrast to earlier reports where there was an 
association between antibody induction therapy and risk of early onset PTLD. (Caillard et 
al., 2005; van Leeuwen et al., 2009) This difference may be related to different eras of 
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treatment and increasing experience with antibody-based induction therapies, leading to an 
attenuation of associated PTLD risks. (Quinlan et al., 2011) 
In contrast, PTLD occurred 2 to 3-fold more frequently after receipt of OKT3 than with other 
drugs. (Opelz & Dohler, 2004; Taylor et al., 2005)  Gajarski et al. report that as induction 
agents thymoglobulin and IL-2R antagonists had the lowest associated PTLD rates 
compared to OKT3, attributing this to its long-lasting depletional effects on CD-3 positive T-
lymphocytes. (Gajarski et al., 2011) IL-2 receptor inhibitor antibodies (daclizumab, 
basiliximab) which specifically target activated T cells and are non-depleting, do not 
increase PTLD risk. Induction with alemtuzumab (anti-CD52 antibody), which depletes both 
T and B lymphocytes, was also not found to be associated with PTLD. (Caillard et al., 2005; 
Kirk et al., 2007; Opelz &Dohler, 2004)  Shapiro et al. reported a small series using 
alemtuzumab as pre-conditioning with tacrolimus monotherapy in pediatric renal 
transplantation, with no cases of PTLD after a median time of follow up of 25 months. 
(Shapiro et al., 2007)  
There are some controversies regarding the risk with the use of calcineurin inhibitors, which 
at this point in time continue as the pillars of maintenance regimens. Although early studies 
suggested the use of tacrolimus increases the risk of PTLD two to fivefold compared to 
cyclosporine, more recent studies suggest that if serum levels are monitored closely, there is 
no difference in risk of PTLD. (Dharnidharka et al., 2001; Guthery et al., 2003; Opelz & 
Dohler, 2004; Russo et al., 2004; Webster et al., 2005) Several groups have shown an 
increased risk of PTLD in kidney transplant recipients receiving tacrolimus compared with 
cyclosporine if they had not received antibody induction, but no difference in the recipients 
that had received induction. (Stojanova et al., 2011) In a recent report patients treated with 
tacrolimus after heart transplantation were at increased risk for the development of PTLD 
compared with patients treated with cyclosporine. (Dayton et al., 2011) Cyclosporine 
increases the risk mainly in higher doses (>6.6 mg/kg per day). (Boubenider et al., 1997) 
Both cyclosporine and tacrolimus inhibited apoptosis in a lymphoblastoid cell line, but it 
has been suggested that a difference in the risk could be due to a higher level of 
immunosuppression with tacrolimus compared to cyclosporine. (Stojanova et al., 2011) 
Some studies have reported that sirolimus may decrease the incidence of PTLD. (Kauffman 
et al., 2005; Yakupoglu et al., 2006)  Conflicting data from the UNOS registry study suggest 
that sirolimus is strongly associated with PTLD in kidney transplant recipients.  The highest 
risk was limited to EBV-seronegative recipients with the clinical implication that sirolimus 
should probably be avoided in this population, especially in those who are already at higher 
risk for PTLD. (Kirk et al., 2007) Nee et al. also noted the same higher risk of PTLD with 
sirolimus, in a retrospective cohort of 53,719 kidney transplant recipients. (Nee et al., 2011) 
It seems that antimetabolites such as azathioprine and mycophenolate mofetil used 
primarily as adjunct therapy alongside calcineurin inhibitors for preventing allograft 
rejection, are associated with a lower or not increased risk of PTLD. (Caillard et al., 2005; 
Kauffman et al., 2005) Mycophenolate mofetil may reduce PTLD risk by allowing the use of 
lower-dose calcineurin inhibitors. (Gajarski et al., 2011)  Belatacept, is a new 
immunosuppressive agent that selectively blocks T-cell co-stimulation. In a recent study 
belatacept was associated with a greater risk of PTLD in the central nervous system (CNS) 
when compared with cyclosporine, especially in EBV-seronegative recipients and when 
used at more intensive doses. (Grinyo et al., 2010)  
www.intechopen.com
 Organ Donation and Transplantation – Public Policy and Clinical Perspectives 
 
154 
In addition to the type of the immunosuppressive drugs, the dosage, the combinations and 
the length of aggressive treatment influence the risk of PTLD, so the total 
immunosuppression exposure rather than induction alone may be a more accurate 
determinant of PTLD risk, and may be modified by choice of induction agent. (Gajarski et 
al., 2011) 
3.4 Type of transplant 
Most analyses suggest that the risk of PTLD is associated with the type of organ 
transplanted. The risk is lowest (1% to 3%) following renal and liver transplantation, 
moderate (1% to 6%) after heart transplantation, and highest after lung (4% to 10%), small 
intestine and multivisceral transplantation (>10% and may be as high as 20% for intestinal 
transplants). (Swerdlow et al; 2008) The reasons for these observed differences in incidence 
of PTLD include recipient factors, such as age and EBV serostatus, but also allograft factors, 
such as differing risk of transmitting EBV-infected B cells (in associated lymphoid tissue) 
with intestine and lung transplants compared with liver, heart, and kidney transplants, and 
the amount of immunosuppression required to prevent rejection. (Opelz & Dohler, 2004; 
Petit et al., 2002; Tsao & Hsi, 2007; Taylor et al., 2005) Among the differences regarding the 
type of organ transplanted is the time of presentation.  Early-onset presentation of PTLD is 
characteristic for heart and lung transplantation, with nearly half of the cases appearing in 
the first year. In contrast among kidney transplant recipients, late-onset presentation is more 
common. This difference is due to higher doses of immunosuppression and induction 
treatment required following heart and lung transplantation. (Quinlan et al., 2011; Taylor et 
al., 2005)  Another difference noted is the origin of the PTLD in renal transplantation-- PTLD 
of donor origin has been described. (Olagne et al., 2011) 
3.5 Other risks 
There are several other risks related to PTLD. A recent study reported that African 
American kidney transplant recipients are at lower risk for PTLD, irrespective of the 
recipient EBV  serostatus. (Nee et al., 2011) Quinlan et al. found that non-Hispanic whites 
were at significantly higher risk of early-onset and late-onset PTLD than other racial or 
ethnic groups. (Quinlan et al., 2011) In the same study it was also demonstrated that CMV-
seronegativity was associated with increased early-onset PTLD risk. (Quinlan et al., 2011) 
However, it seems that the role of CMV and HCV as risk factors for PTLD is controversial, 
as is that of herpes simplex or simian virus infections. (Nee et al., 2011; Tsao & Hsi, 2007) An 
increase in the risk of PTLD has been described in the presence of specific cytokine gene 
polymorphisms. (Taylor et al., 2005; Tsao & Hsi, 2007)  Malignancy and autoimmunity are 
also associated with PTLD. Patients with PTLD are more likely to have a history of pre-
transplant malignancy than those without PTLD. (Caillard et al., 2005; Nee et al., 2011)  
Transplantation due to autoimmune hepatitis and primary biliary cirrhosis carries a higher 
risk of PTLD likely related to chronic immunologic stimulation. (Shpilberg  et al., 1999). 
Transplantation due to cystic fibrosis and Langerhans-cell histiocytosis carries a higher risk 
of PTLD due to a higher incidence of refractory rejection. (Cohen et al., 2000; Newell et al., 
1997) In addition, Zimmermann et al. found that liver recipients who received steroids 
before transplant for immunological disorders are at particularly high risk to develop PTLD. 
(Zimmermann et al., 2010)  
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The role of HLA mismatch in the risk of PTLD is controversial. Among kidney transplant 
recipients, HLA-B mismatches have been reported to increase the risk of lymphoma in the 
allograft, whereas HLA-DR locus mismatches may increase the risk of non-Hodgkin 
lymphoma in the allograft and the central nervous system. (Bakker et al 2005b; Opelz & 
Dohler 2010)  Reshef et al. suggest that the HLA-A26, B38 haplotype is mainly responsible 
for predisposition to PTLD, at least among Caucasian recipients, as an independent risk 
factor. (Reshef et al., 2011) Other studies have been unable to confirm a role for HLA 
mismatches and an increased risk of PTLD. (Nee et al., 2011; Quinlan et al., 2011) 
The assessment of risk factors for PTLD is complicated by the complex nature of the disease 
and the variability among studies with respect to disease definitions, immunosuppression 
protocols and the length of follow up.  Methods of screening for and monitoring of EBV 
have improved over time, as well as the supportive therapy for transplant procedures and 
their complications. As a consequence, there is a tendency toward lower incidence of PTLD; 
it was observed to be less likely to develop in patients who received their allograft after 
1996, than those who received allograft before 1996. (Dayton et al., 2011; Marks et al., 2011; 
Tsao & Hsi 2007) 
4. Diagnosis 
4.1 Clinical presentation 
A high index of suspicion is required for a timely diagnosis of PTLD.  Patients often present 
with relatively benign findings before developing more significant symptomatology. Rarely, 
SOT recipients may present with so-called fulminant PTLD. Other EBV-associated diseases 
must be differentiated from PTLD, although the initial management is similar. (Gross, 2009) 
There are two forms of presentation:  early-onset and late-onset PTLD. Early-onset PTLD 
occurring within 2 to 3 years of transplantation is more common among pediatric SOT 
recipients because of their risk for primary EBV infection. (Opelz & Dohler, 2004)  Early-
onset disease is more likely to involve the allograft and present with declining allograft 
function, excepting heart allografts, in which direct involvement by PTLD is rare. (Bakker et 
al., 2005a) The major differential diagnostic considerations include allograft rejection and 
infection. Later-onset disease is more likely to be EBV negative and to include T/NK-cell 
disease, to involve extranodal sites (especially GI sites) or to present with dissemination. 
(Guthery et al., 2003; Ho et al., 1988; Leblond et al., 1998; Nelson et al., 2000; Steven et al., 
1996)  T/NK-cell disease is rare although it may be increasing, is clinically aggressive and is 
more often EBV negative (two-thirds of cases). (Azhir et al., 2009; Gupta et al., 2010; Miloh et 
al., 2008; Williams et al., 2008; Yang, et al 2008) 
Virtually no site is exempt from PTLD involvement. Outside the allograft, common areas 
affected include lymphoid tissues, GI tract, lung, kidney and liver. Patients may present 
with constitutional symptoms (fever, poor weight gain, rash), mono-type illness, 
lymphadenopathy, and organ dysfunction. A frequent presentation in early-onset disease is 
adenotonsillar involvement with associated sore throat and obstructive symptoms (new 
onset snoring or mouth breathing). (Allen et al., 2005) Involvement of the GI tract may 
present with feeding intolerance, vomiting, diarrhea, protein losses, bleeding, 
intussusception, or obstruction. Perforation may occur at presentation or immediately 
following initiation of therapy in the presence of transmural lesions. New-onset anemia or 
hypoalbuminemia may indicate GI involvement. (Selvaggi et al., 2006) Lung disease may 
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result in unexplained cough, wheezing and respiratory insufficiency or asymptomatic 
nodules. Liver disease may present as an unexplained increase of serum transaminases, 
diffuse hepatitis or nodular lesions. Other signs are joint pain and auto-immune cytopenias. 
PTLD of the central nervous system, isolated or as part of multiorgan disease, may be as 
high as 30%, compared to only 1% among non-Hodgkin lymphomas of the non-transplanted 
population. (Maecker et al., 2007; Taylor et al., 2005)  Patients may present with headache, 
seizures, or focal neurologic findings. 
Some general comments may be made in regard to clinicopathologic correlation. The early-
onset PTLD lesions are generally EBV-related and typically fall into the category of early 
lesions or polymorphic PTLD. In children and adults with late-onset PTLD, EBV-related 
early lesions or polymorphic PTLD may still be observed, but there is a greater percentage 
of monomorphic and EBV-unrelated diseases, especially in adults. (Allen, 2010) However, 
Quinlan et al. in a  retrospective cohort study of kidney transplant recipients, reported that 
early-onset PTLD was more likely to be monomorphic than polymorphic (48.2% vs. 41.6%, 
with 10.2% of unknown), and late-onset PTLD was even more likely to be of monomorphic 
pathology (55.9% vs. 31.4%, 12.7% unknown). Early onset PTLD was predominantly of B-
cell origin, late-onset PTLD showed a slightly higher proportion of T-cell PTLD (64.3% B-cell 
vs. 9.7% T-cell, 25.9% unknown). (Quinlan et al., 2011) 
4.2 Clinical evaluation 
Initial assessment includes a full physical examination with meticulous assessment for 
lymphadenopathy, and a risk adapted approach to the selection of screening evaluations 
and EBV-specific monitoring.  
4.2.1 Screening tests 
Screening tests include a complete blood count with differential, chemistry panel to assess 
for tumor lysis syndrome, allograft function screening, CMV by PCR and other viruses 
(human immunodeficiency virus type 1 & 2, hepatitis B, hepatitis C). Imaging evaluation is 
essential and is directed initially by the location of suspected lesions and prior radiographic 
studies of each patient.  Ultrasound is effective for initial imaging in patients with suspected 
abdominal/pelvic or soft-tissue PTLD.  CT is used in evaluation for neck and chest disease 
and in staging with a suspected or confirmed diagnosis.  Head CT or MRI should be 
included to assess relevant symptoms and in staging evaluations. In patients with 
abdominal symptoms, upper and lower endoscopy should be considered early as lesions 
may be missed on routine imaging. (Allen, 2010)   The role of [18F]2-fluoro-2-deoxyglucose 
(FDG)-positron emission tomography (PET) in the diagnosis of equivocal lesions, staging, 
and response assessment of PTLD is currently being defined. (von Falck, et al 2007) Bakker 
and colleagues demonstrated additional extranodal sites on PET not appreciated on 
computed tomography (CT) in 50% of patients and concordance of PET response with 
outcome. (Bakker et al., 2006) However, false positives have been described when PET is 
used for disease monitoring in children and for the evaluation of lung lesions. (McCormack 
et al., 2006; Rhodes et al., 2006)  Recommended diagnostic procedures are similar to other 
non-Hodgkin lymphoma patients, and staging is completed using the Ann Arbor staging 
system. Diagnosis must be confirmed by biopsy. See Fig. 2 
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Fig. 2. Diagnostic and staging procedures for PTLD. 
4.2.2 EBV-specific tests  
Serology is critical to categorize the serostatus of the donor and recipient at the time of 
transplant. Serology following SOT is unreliable as a diagnostic test in immunocompromised 
patients as they have marked delay in their humoral response.  Primary EBV infection, rather 
than EBV reactivation, is responsible for the majority of PTLD cases in children, and early 
diagnosis may be prompted by serial measurements of EBV DNA in peripheral blood after 
transplant.  An increasing EBV DNA load may be an early sign of PTLD, requiring further 
evaluation and closer monitoring. (Allen, 2010) 
EBV-DNA may be measured in the plasma, peripheral blood mononuclear cells (PBMC) and 
in the whole blood by quantitative PCR assays.  Testing done with plasma measures the cell-
free fraction only and may lead to an underestimation; however the detection of plasma EBV-
DNA is a highly specific test with a high positive predictive value (100%). One possible 
explanation is that free viral DNA is released from latently infected cells, but most notably 
tumor cells undergoing apoptosis. Tsai et al. found EBV-DNA measured in plasma had 
comparable sensitivity and improved specificity compared to whole blood for diagnosis of 
EBV-related PTLD. (Tsai et al., 2008) Measuring intracellular EBV (PBMC) is considered to be 
less specific, due to the high rate of false positivity. In patients with infectious mononucleosis 
viral DNA is detectable in serum for only 7 days after symptom onset and then remains 
detectable in the cellular fraction. Whole blood assays detect EBV-DNA present in the cells and 
in the plasma. Whole blood assays may be better used when screening for PTLD, and plasma 
assays may be better for the evaluation after therapy of PTLD. The time intervals for routine 
monitoring and duration of monitoring may vary depending on the type of transplant and 
individual risk factors. Clinicians must be aware that PTLD may be EBV-unrelated, and that 
EBV-related disease may develop or recur in the absence of an increasing EBV-DNA load. 
(EBV Work Group, Cincinnati Children´s Hopsital Medical Center, 2011; Tsai et al., 2008) 
Adjunctive tests to assess the resiliency of the immune system have been investigated, 
including T-cell restoration or EBV-specific T-cell response. Low T-cell response and high 
EBV-DNA load indicates high degree of immunosuppression and an increased PTLD risk, 
which have to lead a modification of immunosuppression and further examination of the 
New or unexplained 
signs and symptoms 
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patient. Testing of EBV in the CSF is often used to assist in the diagnosis of CNS PTLD and 
avoid the need for more invasive biopsy procedures. (Preiksaitis, 2009) 
5. Treatment 
Treatment strategies for PTLD must be tailored to individual clinical contexts and require 
input from an interdisciplinary team including a transplant specialist, an oncologist and an 
infectious disease specialist. Decisions are based on multiple factors including disease 
presentation, EBV status, patient comorbidities and performance, risk of rejection, type of 
organ graft, and the drugs used for immunosuppressive therapy.  Where impairment of the 
transplanted organ can lead to the death of the patient, the protection of the organ graft is a 
critical factor in planning therapy. 
5.1 Primary prevention 
5.1.1 Donor EBV serologic status 
Avoiding EBV-positive donors in EBV-naive recipients to limit primary infection may 
prevent PTLD. However, only a very small proportion of donors are EBV negative and this 
approach cannot be applied universally. (Lazda, 2006)  
5.1.2 Antiviral therapy 
Increased attention is focused on the prevention of EBV-related PTLD through the use of 
antiviral therapy. Antiviral agents, such as acyclovir and ganciclovir, are nucleoside 
analogues that act by inhibiting the replication of EBV DNA through inhibition of viral 
DNA polymerase. Their activity is dependent on intracellular phosphorylation by virally 
encoded thymidine kinase.  Ganciclovir seems to be more potent and to have a prolonged 
effect. Antiviral therapy may help prevent PTLD in EBV seronegative SOT recipients. 
Cells that are latently infected with EBV and cells of EBV-driven lymphomas do not 
express thymidine kinase. Therefore, these agents would not be expected to be effective in 
EBV-positive PTLD; however, they do limit the lytic replication of EBV-infected cells, 
reduce the viral load, and prevent infection of memory B cells and germinal center cells. 
(Taylor et al., 2005)    
Limited evidence is available to address the efficacy of this therapy in the prevention of 
PTLD and most studies are retrospective, with inherent limitations and contradicting 
results. Prophylactic intravenous ganciclovir after liver transplant in children has been 
associated with decreased incidence of PTLD, perhaps due to reduction in the number of 
latently infected B lymphocytes. (Thorley-Lawson & Gross 2004) Marks et al. report that the 
overall incidence of PTLD was significantly lower when antiviral prophylaxis was used than 
when it was not used or not reported.  They suggest that antiviral drug therapy may affect 
PTLD risk, even when the primary purpose is prevention of CMV infection, as prophylaxis 
may also inhibit EBV reactivation and primary infection, or progression to B-cell 
transformation and PTLD. (Marks et al., 2011) A retrospective study of 3,393 heart 
transplant recipients demonstrated that PTLD incidence did not increase after OKT3 or ATG 
induction therapy when acyclovir or ganciclovir were administered prophylactically. 
(Crespo-Leiro et al., 2007) However, Opelz et al. found in a retrospective study of 44,828 
kidney transplant recipients that ganciclovir or acyclovir had no impact on the development 
of PTLD. (Opelz et al., 2007)  
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There have been small studies that have attempted to use arginine butyrate, an amino acid 
derivative, which induces EBV thymidine kinase expression in latently infected B cells, in 
conjunction with antivirals in the therapy of PTLD. (Oertel & Riess 2002; Perrine et al., 2007)  
This therapy is currently only available in clinical trials. 
5.1.3 Passive and active immunization 
An absence of antibody against at least one of the Epstein-Barr nuclear antigens (EBNA) in 
EBV-seropositive organ transplant recipients has been associated with the subsequent 
development of PTLD. There are also many patients that undergo primary EBV infection 
following transplantation and fail to develop anti-EBNA antibodies. Thus, the absence of 
anti-EBNA antibodies appears to correlate with an increased risk of developing PTLD. 
Increasing levels of anti-EBNA antibodies, including those introduced through transfusion, 
have correlated with decreasing EBV load. All of these data suggest a potential role for 
antibody in controlling EBV infected cells. (Green, 2010)  The potential prophylactic benefit 
of CMV-IVIG against the development of EBV-related PTLD in pediatric liver transplant 
recipients has been evaluated in a randomized multicenter trial. Statistically significant 
differences were not observed, but rates of EBV disease and PTLD were somewhat lower in 
recipients of CMV-IVIG than in those who received placebo. (Green et al., 2006)   One study 
found that anti-CMV immunoglobulin was effective in the prevention of early-onset PTLD 
in kidney transplant patients, but not in the prevention of late-onset PTLD. (Opelz et al., 
2007)   
EBV vaccination may be effective in PTLD prevention, especially in EBV-seronegative 
pediatric transplantation candidates, but the vaccines to date have had no reliable effects on 
the development of cell-mediated immunity. The role of this therapy is still controversial, 
and it is not commercially available. (Posfay-Barbe & Siegrist 2009)  
5.2 Secondary prevention 
5.2.1 Intervention after rising EBV-DNA load 
Development of EBV-associated PTLD is usually preceded by increased levels of EBV-DNA 
load in peripheral blood, typically from 2 to 16 weeks before diagnosis. (Rowe et al., 2001; 
Schubert et al., 2008) EBV-DNA load is higher among SOT recipients subsequently 
diagnosed with PTLD than those who remain disease free.( Bingler, et al 2008; Webber et al., 
1999) There is a trend towards higher EBV loads following primary infection compared with 
reactivation (Kenagy et al., 1995), consistent with the clinical observation of higher risk of 
PTLD following primary infection. (Allen et al., 2005; Ho et al., 1988) Between 60% and 80% 
of EBV-negative children seroconvert within 3 months of transplant (Green & Webber, 2007) 
and a small population maintain high viral loads after primary EBV infection or EBV-
associated PTLD. (Bingler et al., 2008; Green & Webber, 2007)  It is common practice to 
perform biweekly or monthly EBV-DNA load monitoring by quantitative PCR and/or 
immune function monitoring in the immediate post transplantation period with varying 
clinical practice for reduction of immunosuppression (RI), use of antiviral agents, use of 
monoclonal anti-CD20 (Rituximab) or cellular therapy in the event of rising EBV-DNA load. 
Which form of pre-emptive therapy is best to prevent PTLD is unclear at this time. 
In pediatric liver transplant recipients, monitoring EBV-DNA loads in the first 6 months 
after transplant with RI and initiation of ganciclovir at the time of rise in EBV-DNA load 
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resulted in a 50% reduction in the incidence of PTLD. (McDiarmid et al., 1998; Stevens, et al., 
2002) In 73 pediatric liver transplant patients treated during 2001– 2004, the incidence of 
PTLD was reduced from 16 to 2% by RI in individuals with a high EBV load. (Lee, et al 2005) 
Series of pediatric intestinal transplant recipients reported similar results. (Green et al., 2000; 
Krieger, et al 2000)  Rituximab is generally well tolerated and rapidly induces the depletion 
of mature B-lymphocytes, reducing the compartment of EBV infected cells, with an 
associated normalization of the viral load. It has been successfully used as a preemptive 
treatment for PTLD, specifically in the HSCT population. (Comoli et al., 2007; Styczynski et 
al., 2009)  A preliminary report of adult cardiac recipients given rituximab as pre-emptive 
therapy, showed that only one patient (n=251) developed PTLD. (Choquet et al., 2011)  This 
approach merits further evaluation for widespread application. 
5.2.2 Cellular therapy 
Recognizing the critical role of EBV-specific cytotoxic T-cells (CTLs) in immune surveillance, 
cellular therapy is considered both a preventive and therapeutic strategy with initial 
experience in EBV-related PTLD following HSCT. (Rooney et al., 1998) The implementation 
of this therapy in SOT it is more problematic where PTLD is primarily of recipient origin 
and often occurs in patients who are EBV seronegative prior to transplant. Some of the 
problems with the use of individual-based EBV-specific CTLs are the cost and the 
processing time required to generate the cells. Moosmann et al. recently reported a system 
that allowed the rapid isolation and generation of clinical-grade EBV-specific CTLs for the 
treatment of HSCT-related PTLD. (Moosmann et al., 2010) An alternative is to use allogeneic 
CTLs closely matched with human leukocyte antigen (HLA) from donors who are EBV 
seropositive.  In a phase II multicenter clinical trial, relapsed and refractory PTLD patients 
were treated by weekly intravenous allogeneic CTL infusions for 4 weeks.  No adverse 
effects were observed and the response rate was 64% at 5 weeks and 52% at 6 months in 33 
patients. (Haque et al., 2007)  Commercial banks of EBV specific CTLs generated from the 
peripheral blood of EBV-positive blood donors are in development.  In the SOT setting, 
there is often the need to continue immunosuppression and this impairs the efficacy of 
adoptive T-cell therapy.  In a effort to solve this problem, two groups have generated EBV-
based CTLs resistant to calcineurin inhibitors and have shown efficacy of this approach 
without requiring a reduction in immunosuppression. (Brewin et al., 2009; Haque et al., 
2007) EBV specific CTL therapy is now recommended for persistent or progressive EBV 
driven polymorphic or monomorphic PTLD. (NCCN Guidelines Version 4.2011) 
5.3 Therapy 
5.3.1 Reduction in immunosuppression (RI) 
The initial approach to managing patients with PTLD is RI, which might restore CTL 
function and elicit a favorable response in EBV-positive PTLD. The dosage of 
immunosuppressive drugs must be reduced by 25%–50% of the normal therapeutic whole 
blood level. This approach is most effective for early lesions and polymorphic disease and 
for those patients diagnosed early following transplantation. (Cheema et al., 2008; Nelson et 
al., 2000; Taylor et al., 2005) The long term remission rate of early lesions and polymorphic 
PTLD treated with RI is 40%–86% in children but considerably lower in adults. (Carbone, et 
al 2008, Green, et al 1999; Taylor et al., 2005) In many cases additional therapy is required 
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(Reshef R et al., 2009). Lack of response to RI has been associated with elevated LDH at 
presentation, organ dysfunction, late-onset PTLD, and multiorgan involvement. The median 
time to response of RI is 2 to 4 weeks; patients with aggressive disease or high tumor burden 
often warrant more immediate treatment. The risk of graft rejection must be considered 
before RI. (Caillard, et al 2005) The risk of acute rejection may be reduced by the 
administration of corticosteroids, which are also important components of most 
chemotherapy regimens for PTLD. (Taylor et al., 2005)   RI is generally well tolerated among 
liver and renal transplant recipients with non-invasive screening available for detection, and 
decreased risk and relative tolerability, of organ rejection; indeed complete withdrawal of 
immunosuppression may be possible in selected liver transplant recipients. (Londono et al., 
2010; Tsai et al., 2001) RI strategy is not standardized. Differences of aggressiveness and 
duration of RI, amount of time to evaluate response prior to initiating second-line treatment, 
and patient factors (type of transplant, extent of disease, time from transplant and 
immunosuppression history), may explain reported differences in outcomes. 
5.3.2 Chemotherapy and rituximab 
Chemotherapy and/or rituximab are commonly used when RI fails to control the disease, and 
as an initial therapy for aggressive, monoclonal PTLD. Low dose chemotherapy may decrease 
toxic complications seen in immunosuppressed patients, but may lead to higher relapse rates. 
(Gross, et al 2005)  The use of anti-CD20 antibody therapy (rituximab) as a single agent has 
been associated with overall response rates of 37–69% and is potentially beneficial and less 
toxic than systemic chemotherapy. (Blaes et al., 2005; Orjuela, et al 2003) 
Rituximab/chemotherapy (R/C) combination has been examined in an attempt to improve 
response rates. (Evens et al., 2010) Gupta et al., reported an overall response rate of 100% in the 
patients treated with R/C combination (low dose of chemotherapy) with a recurrence rate of 
only 12% and 2-year failure free survival of 80%. (Gupta et al ., 2010)  Orjuela et al., in a pilot 
multi-center study of pediatric patients treated with cyclophosphamide, prednisone and 
rituximab, report an overall response rate of 100% (five complete response [CR] and one 
partial response) with a median follow-up of 12.5 months. (Orjuela, et al 2003) A recent single-
center study reported a two year OS and EFS of 85.7% and 57%, respectively, with a 
combination of rituximab and a milder chemotherapy regimen. (Gallego et al., 2010) Trappe et 
al have recommended a risk stratified approach based on upfront  response to 4 weekly doses 
of rituximab: patients with a complete response (CR) to rituximab continued to receive an 
additional 4 doses of rituximab alone whereas patients with less than a CR subsequently 
received rituximab plus CHOP chemotherapy for four cycles with growth factor support. 
Using this approach, the overall response rate was 89%. (Trappe et al., 2009)  Rituximab as a 
single agent is a consideration for many patients, with the use of combination chemotherapy 
for progressive or relapsed disease or for patients with concomitant allograft rejection.  
Some groups have tried to identify at diagnosis patients likely to have a poor response to 
rituximab monotherapy. One study suggested that good response in late PTLD was only 
seen when rituximab was used after either surgical resection or radiotherapy (Dotti et al, 
2001) and, in another, EBV-negative PTLD did not respond to rituximab and subsequently 
required chemotherapy (Oertel et al, 2005). The recommendation of the British Committee 
for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) 
guidelines for adults is that rituximab plus chemotherapy should be used for patients who 
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fail to respond within 8 weeks of rituximab plus RI and it should be considered immediately 
at any stage following diagnosis for patients with clinically aggressive disease or those with 
critical organ compromise (Parker et al, 2010). 
Chemotherapy is used as a first line therapy for Burkitt lymphoma, T-cell disease and for 
most cases of Hodgkin lymphoma. Burkitt lymphoma seems to respond well to immediate 
aggressive chemotherapy. (Picarsic et al., 2010) Hodgkin disease is often associated with 
EBV and responds well to standard therapy. (Bierman et al., 1996) Available literature 
suggests that T -cell PTLD is clinically aggressive and may be associated with a poor 
prognosis. (Azhir et al., 2009; Gupta et al., 2010, Miloh et al., 2008; Williams et al., 2008; 
Yang, et al 2008) 
5.3.3 Isolated CNS PTLD 
CNS disease has been associated with significantly inferior survival, compared with non-
CNS PTLD. (Buell et al., 2005; Knight et al., 2009; Maecker et al., 2007) It is more commonly 
associated with EBV. (Choquet et al., 2008) The optimal therapy for CNS PTLD is not known 
and proposed treatment approaches include high-dose methotrexate-based therapy, 
intrathecal chemotherapy and intrathecal rituxumab. (Bonney et al., 2011; Choquet et al., 
2008; Taj et al., 2008; van de Glind et al., 2008) 
5.3.4 Surgery and radiation  
Resection of a total solitary lesion may be curative, but is usually combined with RI. (Allen, 
et al 2001) Radiation is rarely used but may be considered when rapid local responses are 
required (eg. airway compression) and in some cases of CNS PTLD. 
5.3.5 Relapsed/refractory disease 
There is no standard recommendation for relapsed or refractory PTLD.  Trappe et al. have 
shown that rituximab may still lead to response in patients who fail chemotherapy, and 
chemotherapy might lead to response in patients with failure after rituximab. (Trappe et al., 
2007a, 2007b) In addition, autologous hematopoietic stem cell transplantation has been 
reported as a viable treatment option for relapsed PTLD. (Amar et al., 2006) The role for 
cellular therapy in this context was reviewed above. 
6. Prognosis 
Although there has been improvement over time for patient and graft survival, outcomes 
after PTLD remain suboptimal. Survival after PTLD differs by recipient age and allograft 
type. Outcomes for children with PTLD are much better than for adults. (Dharnidharka, 
2010)  Outcomes are highest for recipients of renal and liver allografts, with survival rates 
for children reported at 89% and 80% respectively (Fernandez et al., 2009; McDonald et al., 
2008), but significantly lower for other types of transplant, 67% at five years in heart 
transplant recipients, 54% and 42% at 3 and 5 years respectively in lung transplant 
recipients. (Cohen et al., 2000; Webber et al., 2006) Further, the overall survival according to 
stage is 80% for stages I/II, 61% for stage III, 20% for CNS involvement and less than 20% 
for BM involvement. The overall survival success for mild to moderate PTLD cases seemed 
similar across the various treatment options. (Maecker et al., 2007)  
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7. Conclusions 
Patients with PTLD present a multifaceted clinical challenge balancing cure, allograft 
function and other co-morbidities. The epidemiology of PTLD appears to be changing with 
the median time of presentation trending later and the percentage of monomorphic and EBV 
negative disease increasing concomitant with changing immunosuppression practices, 
improved identification of patients at risk, and early introduction of RI.   Even with these 
advances some patients have a good initial response to therapy without a long remission, 
and the mortality rates remain high.  There is an ongoing need for coordinated care 
programs and clinical practice guidelines for a consistent approach to care and to further 
research programs.  Novel therapeutic approaches aimed at restoration of immune 
surveillance should continue to be examined. 
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